MedTrace Logo

Intravenous Lidocaine for Cystectomy Procedures

NCT02924480 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2022-03-09

No results posted yet for this study

Summary

Patients scheduled for a cystectomy at Charleston Area Medical Center (CAMC) will be enrolled into a randomized, double blinded clinical trial to assess if postoperative pain and ileus are reduced by perioperative intravenous lidocaine infusion versus placebo. The hypothesis is that patients receiving the lidocaine infusion will experience better pain control and ileus resolution. It is believed that lidocaine patients will also have less opioid requirement, less mortality, a shorter length of stay, less nausea /vomiting, and fewer adverse events.

Conditions

  • Invasive Bladder Cancer

Interventions

PROCEDURE

Cystectomy

DRUG

Lidocaine

Patients will receive lidocaine infusion during surgery

DRUG

Saline

Patients will receive saline infusion during surgery

Sponsors & Collaborators

  • CAMC Health System

    lead OTHER

Principal Investigators

  • Samuel G Deem, DO · CAMC Health System

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-10-12
Primary Completion
2020-06-17
Completion
2020-06-17

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02924480 on ClinicalTrials.gov